Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.56 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23451325 | 1.00 | HTT (0.72) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL7760301 | 0.90 | HTT (0.62) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL29467703 | 0.88 | HTT (0.57) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL30407736 | 0.88 | HTT (0.57) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL9006385 | 0.86 | HTT (0.57) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL29467716 | 0.85 | HTT (0.53) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL23451372 | 0.85 | SYK (0.54) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL23451373 | 0.85 | SYK (0.54) | HTTCAPN1CAPN2CTSLCTSS | |
| SCHEMBL319161 | 0.84 | HTT (1.00) | HTTFOLH1ATM | |
| SCHEMBL9113504 | 0.84 | CA2 (0.67) | HTTCAPN1CAPN2CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169896-A1 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | PBDC1, BRD2, CD79B | HTT 3654/4885CAPN1 2714/4885CAPN2 2517/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | HTT 3275/4885CAPN1 1848/4885CAPN2 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.